Michael Wyand, PhD, Chief Executive Officer/Director, Oxeia Biopharmaceuticals explains why there’s a need for new drugs to treat traumatic brain injuries. Whereas once it was thought that mild traumatic brain injuries were harmless and symptoms would disappear after a few days of rest, we now know that rest is not enough – these are   […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!